Abstract
The pharmacokinetics of terbinafine and its inactive metabolites SDZ 86-621 (the N-demethyl form), SDZ 280-027 (the carboxybutyl form), and SDZ 280-047 (N-demethyl- carboxybutyl form) in plasma were characterized for 10 healthy male subjects receiving 250 mg of terbinafine orally once a day for 4 weeks and in the subsequent 8-week washout phase. Terbinafine concentrations were also measured in sebum, hair, nail, and stratum corneum samples. Concentrations of the parent compound and metabolites were determined by validated high-performance liquid chromatography methods. Terbinafine was rapidly absorbed, with peak concentrations in plasma of 1.70 +/- 0.77 micrograms/ml occurring 1.2 +/- 0.3 h postdose. Concentrations subsequently exhibited a triphasic decline, with a terminal deposition half-life of 16.5 +/- 2.8 days. Terbinafine accumulated approximately twofold over the 4-week dosing phase. The predominant metabolite in plasma samples was SDZ 280-027; specifically, the ratios of metabolite area under the curve to terbinafine area under the curve following the last dose were 1.25, 1.38, and 1.08 for metabolites SDZ 86-621, SDZ 280-027, and SDZ 280-047. Measurable concentrations of terbinafine were achieved in sebum and hair samples within the first week of administration and by week 3 in stratum corneum and nail samples. Fungicidal concentrations persisted in plasma and peripheral tissue samples for prolonged periods (weeks to months) after administration of the last dose. These pharmacokinetic properties are likely an underlying factor in the shorter treatment times and good clinical cure rates which have been reported for terbinafine in the therapy of onychomycoses and dermatomycoses.
Full Text
The Full Text of this article is available as a PDF (199.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balfour J. A., Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992 Feb;43(2):259–284. doi: 10.2165/00003495-199243020-00010. [DOI] [PubMed] [Google Scholar]
- Denouël J., Keller H. P., Schaub P., Delaborde C., Humbert H. Determination of terbinafine and its desmethyl metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995 Jan 20;663(2):353–359. doi: 10.1016/0378-4347(94)00449-f. [DOI] [PubMed] [Google Scholar]
- Faergemann J., Zehender H., Denouël J., Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993 Aug;73(4):305–309. doi: 10.2340/000155557300304. [DOI] [PubMed] [Google Scholar]
- Jensen J. C. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol. 1989 Mar;14(2):110–113. doi: 10.1111/j.1365-2230.1989.tb00904.x. [DOI] [PubMed] [Google Scholar]
- Kovarik J. M., Kirkesseli S., Humbert H., Grass P., Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol. 1992 Feb;126 (Suppl 39):8–13. doi: 10.1111/j.1365-2133.1992.tb00002.x. [DOI] [PubMed] [Google Scholar]
- Petranyi G., Meingassner J. G., Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987 Sep;31(9):1365–1368. doi: 10.1128/aac.31.9.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zehender H., Denouël J., Roy M., Le Saux L., Schaub P. Simultaneous determination of terbinafine (Lamisil) and five metabolites in human plasma and urine by high-performance liquid chromatography using on-line solid-phase extraction. J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):347–355. doi: 10.1016/0378-4347(94)00483-l. [DOI] [PubMed] [Google Scholar]
- van der Schroeff J. G., Cirkel P. K., Crijns M. B., Van Dijk T. J., Govaert F. J., Groeneweg D. A., Tazelaar D. J., De Wit R. F., Wuite J. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992 Feb;126 (Suppl 39):36–39. doi: 10.1111/j.1365-2133.1992.tb00008.x. [DOI] [PubMed] [Google Scholar]